Trevi Therapeutics’ (TRVI) Buy Rating Reiterated at B. Riley
B. Riley restated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. B. Riley currently has a $20.00 price objective on the stock, up from their prior price objective of $11.00. B. Riley also issued estimates for Trevi Therapeutics’ Q2 2025 […]
B. Riley restated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. B. Riley currently has a $20.00 price objective on the stock, up from their prior price objective of $11.00. B. Riley also issued estimates for Trevi Therapeutics’ Q2 2025 […]
